Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$15.98 +1.2%	$14.71	$8.03 ▼ $17.75	$1.89B	1.84	1.81 million shs	1.41 million shs
IRON Disc Medicine	$60.35 +1.0%	$56.87	$30.82 ▼ $68.73	$2.08B	0.77	332,509 shs	349,244 shs
MESO Mesoblast	$15.81 +4.2%	$13.38	$6.00 ▼ $22.00	$1.94B	2.4	151,117 shs	162,232 shs
OPT Opthea	$3.41 +7.2%	$3.41	$1.79 ▼ $6.30	$524.84M	1.17	N/A	3,000 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	+1.20%	-5.39%	+7.18%	+14.31%	+91.61%
IRON Disc Medicine	+1.00%	+0.82%	-0.97%	+27.40%	+22.39%
MESO Mesoblast	+4.22%	-2.71%	-1.74%	+45.71%	+142.86%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	+19.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	2.7404 of 5 stars	3.4	2.0	3.5	1.7	0.6
IRON Disc Medicine	3.4812 of 5 stars	4.5	3.0	2.5	2.5	0.0
MESO Mesoblast	2.0759 of 5 stars	2.6	4.0	2.5	0.8	0.6
OPT Opthea	0.2698 of 5 stars	1.1	0.0	1.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.86	Moderate Buy	$19.80	23.90% Upside
IRON Disc Medicine	3.09	Buy	$98.30	62.88% Upside
MESO Mesoblast	3.20	Buy	$18.00	13.85% Upside
OPT Opthea	2.17	Hold	$1.33	-60.90% Downside

Current Analyst Ratings Breakdown

Latest OPT, IRON, MESO, and ARQT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$85.00 ➝ $90.00
8/7/2025	ARQT Arcutis Biotherapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
8/5/2025	MESO Mesoblast	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/25/2025	ARQT Arcutis Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00
7/21/2025	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/21/2025	IRON Disc Medicine	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$86.00
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/3/2025	IRON Disc Medicine	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
7/3/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00
6/17/2025	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$118.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$263.47M	7.27	N/A	N/A	$1.16 per share	13.78
IRON Disc Medicine	N/A	N/A	N/A	N/A	$17.67 per share	N/A
MESO Mesoblast	$5.90M	343.00	N/A	N/A	$4.21 per share	3.76
OPT Opthea	$120K	4,373.61	N/A	N/A	($0.56) per share	-6.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$140.04M	-$0.75	N/A	N/A	N/A	-35.40%	-62.62%	-25.16%	11/5/2025 (Estimated)
IRON Disc Medicine	-$109.36M	-$4.47	N/A	N/A	N/A	N/A	-26.60%	-24.58%	11/11/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/27/2025 (Estimated)
OPT Opthea	-$220.24M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/29/2025 (Estimated)

Latest OPT, IRON, MESO, and ARQT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	H2 2025	MESO Mesoblast	-$0.20	N/A	N/A	N/A	$7.48 million	N/A
8/7/2025	Q2 2025	IRON Disc Medicine	-$1.17	-$1.58	-$0.41	-$1.58	N/A	N/A
8/6/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$72.70 million	$81.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.77	3.20	3.04
IRON Disc Medicine	0.05	32.11	32.11
MESO Mesoblast	0.22	0.96	0.63
OPT Opthea	N/A	1.57	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
IRON Disc Medicine	83.70%
MESO Mesoblast	1.43%
OPT Opthea	55.95%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
IRON Disc Medicine	3.64%
MESO Mesoblast	18.80%
OPT Opthea	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.91 million	108.63 million	Optionable
IRON Disc Medicine	30	34.77 million	33.50 million	Not Optionable
MESO Mesoblast	80	128.00 million	103.93 million	Optionable
OPT Opthea	8	153.91 million	148.99 million	Not Optionable

OPT, IRON, MESO, and ARQT Headlines

Recent News About These Companies

Opthea Limited Provides Corporate Update in Investor Presentation

August 20 at 2:02 AM | msn.com

Opthea parts with CEO, lays off over 80% of company

August 19, 2025 | ophthalmologytimes.comO

Opthea Provides Corporate Update

August 18, 2025 | globenewswire.com

Regal Partners Ltd Has $17.71 Million Position in Opthea Limited Unsponsored ADR (NASDAQ:OPT)

August 14, 2025 | marketbeat.com

Opthea (NASDAQ:OPT) Stock Price Up 7.2% - What's Next?

July 26, 2025 | marketbeat.com

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected

July 2, 2025 | msn.com

Opthea Faces Leadership Changes Amidst Clinical Trial Setbacks

June 1, 2025 | tipranks.com

Biotech Dimerix lands $940m licensing deal for kidney drug sales

May 1, 2025 | afr.com

Phil King’s Regal successfully bets against Tesla, Nvidia

May 1, 2025 | afr.com

'No one is happy': Regal stockpickers face financial hit after Opthea blow up

April 21, 2025 | capitalbrief.comC

Regal’s King says his hedge funds will recover from March madness

April 16, 2025 | afr.com

Regal: Don’t catch the falling knife, wait for it to stick in the floor

April 16, 2025 | msn.com

Opthea to lay off approximately 65% of company

April 10, 2025 | ophthalmologytimes.comO

Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops

April 10, 2025 | fiercebiotech.comF

BELL POTTER SECURITIES Downgrades Opthea (CKDXF)

April 9, 2025 | msn.com

BELL POTTER SECURITIES Downgrades Opthea Limited - Depositary Receipt () (OPT)

April 9, 2025 | msn.com

ASX drops as US jumbo China tariff takes effect

April 9, 2025 | afr.com

Opthea Limited (CKDXF) was downgraded to a Sell Rating at Bell Potter

April 3, 2025 | markets.businessinsider.com

Phil King’s Regal writes Opthea to zero and backs off risky bets

April 2, 2025 | afr.com

Opthea Ends Development of Sozinibercept in Wet AMD

March 31, 2025 | marketwatch.com

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

March 31, 2025 | endpts.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPT, IRON, MESO, and ARQT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$15.98 +0.19 (+1.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.95 -0.03 (-0.18%)

As of 08/22/2025 07:56 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Disc Medicine NASDAQ:IRON

$60.35 +0.60 (+1.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$61.00 +0.65 (+1.08%)

As of 08/22/2025 05:45 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Mesoblast NASDAQ:MESO

$15.81 +0.64 (+4.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.78 -0.03 (-0.19%)

As of 08/22/2025 06:02 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Opthea NASDAQ:OPT

$3.41 +0.23 (+7.23%)

As of 08/21/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time